NASDAQ:MLNTMelinta Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$0.35MA: $0.48▼$0.5052-Week Range N/AVolumeN/AAverage Volume713,628 shsMarket Capitalization$6.88 millionP/E RatioN/ADividend YieldN/ABeta4.16 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingMelinta Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Melinta Therapeutics has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageMelinta Therapeutics has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMelinta Therapeutics has received 632 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMelinta Therapeutics has received 518 “underperform” votes. (Add your “underperform” vote.)Community SentimentMelinta Therapeutics has received 54.96% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote “Outperform” if you believe MLNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMelinta Therapeutics does not currently pay a dividend.Dividend GrowthMelinta Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Melinta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders60.30% of the stock of Melinta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.02% of the stock of Melinta Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Melinta Therapeutics are expected to grow in the coming year, from ($6.85) to ($4.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Melinta Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Melinta Therapeutics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:MLNT Previous Symbol CUSIP15130J10 CIK1461993 Webwww.melinta.com Phone908-617-1309Debt Debt-to-Equity Ratio1.11 Current Ratio1.03 Quick Ratio0.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$96.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$16.96 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($17.72) Net Income$-157,190,000.00 Net Margins-393.39% Return on Equity-101.29% Return on Assets-28.68%Miscellaneous Employees290 Outstanding Shares13,750,000Market Cap$6.88 million Next Earnings DateN/A OptionableOptionable Receive MLNT News and Ratings via Email Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Melinta Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Melinta Therapeutics. How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics Inc (NASDAQ:MLNT) posted its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing the Zacks' consensus estimate of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analyst estimates of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative return on equity of 101.29%. View Melinta Therapeutics' earnings history. When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work? Melinta Therapeutics shares reverse split on the morning of Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split. What price target have analysts set for MLNT? 1 brokers have issued 12 month target prices for Melinta Therapeutics' stock. Their forecasts range from $13.00 to $13.00. On average, they expect Melinta Therapeutics' stock price to reach $13.00 in the next twelve months. View analysts' price targets for Melinta Therapeutics. What are Wall Street analysts saying about Melinta Therapeutics stock? Here are some recent quotes from research analysts about Melinta Therapeutics stock: 1. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (1/15/2020) 2. HC Wainwright analysts commented, "We note that after a brief spike to $4.98 late Tuesday morning, MLNT shares closed last night at $3.75 per share, down $0.43 (-10.3%) since the release, versus NBI essentially flat (-0.4%) over the same period. First, the expected net product sales figure of $13.8M in the quarter is a slight 3% increase from our recently-lowered prior estimate of $13.4M. for CABP by Adjust PT to $13. We have now adjusted our estimate to match guidance. However, with 1H19 net product sales at about $25.6M, net sales growth in 2H19 would need to be at least 49% over 1H19 to meet the full-year 2019 minimum product sales of $63.75M as required by the Deerfield debt facility. This degree of growth acceleration seems unlikely to us the sequential growth in 2Q19 was 17%." (7/18/2019) Has Melinta Therapeutics been receiving favorable news coverage? Press coverage about MLNT stock has been trending neutral this week, according to InfoTrie. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Melinta Therapeutics earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Melinta Therapeutics. Who are some of Melinta Therapeutics' key competitors? Some companies that are related to Melinta Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Melinta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Advanced Micro Devices (AMD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Nabriva Therapeutics (NBRV), NVIDIA (NVDA) and Novavax (NVAX). Who are Melinta Therapeutics' key executives? Melinta Therapeutics' management team includes the following people: Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)Mr. John H. Johnson, CEO & Director (Age 61)Dr. Thomas A. Steitz, Co-FounderDr. Peter B. Moore Ph.D., Co-FounderDr. William L. Jorgensen, Co-Founder What is Melinta Therapeutics' stock symbol? Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT." How big of a company is Melinta Therapeutics? Melinta Therapeutics has a market capitalization of $0.00 and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe. What is Melinta Therapeutics' official website? The official website for Melinta Therapeutics is www.melinta.com. How can I contact Melinta Therapeutics? Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected] This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
